PHARMACEUTICAL
COMPANIES

Do you have a new DRUG CANDIDATE for Glaucoma or AMD?

761-hd-loop-min.gif

Pharmaceutical development is beset with problems which are well understood.

Only 1 in 5000 molecules make it into clinical programmes.
Only 12% of new drug candidates make it through clinical trials, with only 20% of these achieving a successful ROI.
The average time to market for a new drug candidate is 12 years. 

DARC de-risks these common problems in glaucoma & AMD drug discovery.

 

HOW CAN DARC HELP YOU?

 
PHARMA-3-_-TEST.png

DARC DE-RISKS & ADDS VALUE IN GLAUCOMA & AMD DRUG DEVELOPMENT

Find out if your new drug candidate works within weeks.

Identify the most effective dosage of your new drug candidate within weeks.

Identify the patients with the most active disease.

Identify the patients who will show the fastest progression of disease.

Identify anatomical regions with active disease.

Identify non-effective drug candidates within weeks.

DARC saves your company time & money.

 
 
 
PHARMA-1-_-TEST.png

TRIAL DESIGN & OUTCOME OPTIMISATION

DARC will enable cost effective assessment of potential drug candidates.

DARC can identify patients who will demonstrate faster progression of disease based on conventional end points.

DARC can predict disease progression 18 months before conventional end points.

Using DARC as a triaging agent can enrich your patient pool to maximise trial outcomes.

DARC identifies the leading edge of disease activity in geographic atrophy (GA).

DARC can pin-point anatomical disease activity, allowing targeted gene therapy intervention.

 
PHARMA-2-_-TEST.png

DRUG EFFICACY

DARC can identify if your new drug candidate is effective in weeks instead of months/years.

Gene therapy agents can be injected into relevant anatomical sites.

DARC will allow you to assess your drug candidates relative efficacy.

DARC will allow you to mitigate the risk of efficacy related clinical failure.

 
 

If you want to maximise your chances of trial success, use DARC.